Cavinton Forte, tablets 10 mg 30 pcs

Cavinton is a drug that improves cerebral circulation, cerebral metabolism and rheological properties of the blood.

It has cerebroprotective effect. It reduces severity of damaging cytotoxic reactions caused by stimulating amino acids; it inhibits functional activity of both cellular transmembrane sodium and calcium channels and NMDA and AMPA receptors. Potentiates neuroprotective effect of adenosine.

Stimulates brain metabolism, increases absorption and assimilation of glucose and oxygen by the brain. Stimulates the transport of glucose through the GEB, shifts glucose metabolism in an energetically more favorable aerobic direction.

It selectively inhibits Ca²⁺-calmodulin-dependent cGMP-phosphodiesterase, increases the concentration of cAMP and cGMP in brain tissue, as well as ATP concentration and ATP/AMP ratio. It stimulates cerebral metabolism of noradrenaline and serotonin, stimulates the ascending noradrenergic system and has an antioxidant effect.

The drug selectively increases cerebral blood flow: increases cerebral fraction of minute volume; decreases resistance of cerebral vessels without affecting parameters of total blood circulation (BP, minute volume, HR, RPS).

It does not cause the phenomenon of “stealing”; on the contrary, its use primarily increases the blood supply to the ischemic, but still viable area with low perfusion – the phenomenon of “reverse stealing”.

It improves the tolerance of hypoxia by brain cells by promoting the transport of oxygen to the tissues by reducing the affinity of red blood cells for it.
The drug improves microcirculation in the brain, inhibits platelet aggregation, reduces abnormally high blood viscosity, increases the deformability of red blood cells and blocks their absorption of adenosine.

Pharmacokinetics

Therapeutic plasma concentration is 10-20 ng/ml. When parenteral administration, V_d is 5.3 l/kg. T_1/2 – 4.74-5 hours. Easily penetrates through histohematic barriers (including the GEB). It is excreted by the kidneys and through the gastrointestinal tract in the ratio of 3:2.

Indications

In neurology

In ophthalmology: vascular eye diseases (atherosclerosis, angiospasm of the choroid and retina, degenerative diseases of the choroid, retina or yellow spot, arterial and venous thrombosis or embolism, secondary glaucoma).

In ENT practice

Active ingredient

Composition

1 tablet contains:

acting substance:

vinpocetine 10 mg;

excipients:

colloidal silica anhydrous,

magnesium stearate,

talc,

starch,

lactose.

How to take, the dosage

The course of treatment and dosage is determined by the doctor.

In most cases, 1 tablet (10 mg) 3 times a day is taken.

Cavinton should be taken after meals.

The course of 1 to 8 months, on average 3 to 4 months.

If the drug is withdrawn, the dose of Cavinton is reduced within 2-3 days.

Interaction

It is not observed when concomitant use with pindolol, clopamide, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide; imipramine.

In rare cases, concomitant use with α-methyldopa is accompanied by some increase in the hypotensive effect, and regular BP control is required with this combination.

While there is no data to support the possibility of interaction, caution is recommended when concomitant use with central, antiarrhythmic, and anticoagulant drugs.

Special Instructions

The presence of prolonged QT interval syndrome and concomitant use of drugs that cause prolongation of the QT interval necessitate periodic ECG monitoring.

Cavinton tablets contain lactose.

Contraindications

Side effects

Cardiovascular system disorders: aggravation of existing arrhythmias is possible.

Digestive system disorders: nausea, heartburn, dry mouth.

CNS disorders: headache, dizziness, insomnia, weakness.

Allergic reactions: skin rash, urticaria.

Skin reactions: skin hyperemia.

Overdose

There are currently limited data on vinpocetine overdose.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

Pregnancy use

It is contraindicated in pregnancy. Vinpocetine penetrates the placental barrier.

In this case its concentration in the placenta and fetal blood is lower than in the blood of the pregnant woman.

In high doses placental bleeding and spontaneous abortions are possible, probably as a result of increased placental blood supply. Within one hour, 0.25% of the taken dose of the drug penetrates into the breast milk.

Breastfeeding should be stopped when using the drug.

Similarities